209 related articles for article (PubMed ID: 16778180)
1. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Furuta J; Nobeyama Y; Umebayashi Y; Otsuka F; Kikuchi K; Ushijima T
Cancer Res; 2006 Jun; 66(12):6080-6. PubMed ID: 16778180
[TBL] [Abstract][Full Text] [Related]
2. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
[TBL] [Abstract][Full Text] [Related]
3. Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers.
Hagihara A; Miyamoto K; Furuta J; Hiraoka N; Wakazono K; Seki S; Fukushima S; Tsao MS; Sugimura T; Ushijima T
Oncogene; 2004 Nov; 23(53):8705-10. PubMed ID: 15467763
[TBL] [Abstract][Full Text] [Related]
4. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
Nobeyama Y; Okochi-Takada E; Furuta J; Miyagi Y; Kikuchi K; Yamamoto A; Nakanishi Y; Nakagawa H; Ushijima T
Int J Cancer; 2007 Jul; 121(2):301-7. PubMed ID: 17372906
[TBL] [Abstract][Full Text] [Related]
5. Aberrant p27Kip1 promoter methylation in malignant melanoma.
Worm J; Bartkova J; Kirkin AF; Straten P; Zeuthen J; Bartek J; Guldberg P
Oncogene; 2000 Oct; 19(44):5111-5. PubMed ID: 11042700
[TBL] [Abstract][Full Text] [Related]
6. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis.
Abe M; Watanabe N; McDonell N; Takato T; Ohira M; Nakagawara A; Ushijima T
Oncology; 2008; 74(1-2):50-60. PubMed ID: 18544995
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
9. Larger numbers of silenced genes in cancer cell lines with increased de novo methylation of scattered CpG sites.
Moriguchi K; Yamashita S; Tsujino Y; Tatematsu M; Ushijima T
Cancer Lett; 2007 May; 249(2):178-87. PubMed ID: 16971039
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
11. Identification of silencing of nine genes in human gastric cancers.
Kaneda A; Kaminishi M; Yanagihara K; Sugimura T; Ushijima T
Cancer Res; 2002 Nov; 62(22):6645-50. PubMed ID: 12438262
[TBL] [Abstract][Full Text] [Related]
12. Features and trend of loss of promoter-associated CpG islands in the human and mouse genomes.
Jiang C; Han L; Su B; Li WH; Zhao Z
Mol Biol Evol; 2007 Sep; 24(9):1991-2000. PubMed ID: 17591602
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
14. CpG islands--'a rough guide'.
Illingworth RS; Bird AP
FEBS Lett; 2009 Jun; 583(11):1713-20. PubMed ID: 19376112
[TBL] [Abstract][Full Text] [Related]
15. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation.
Stengel S; Fiebig U; Kurth R; Denner J
Genes Chromosomes Cancer; 2010 May; 49(5):401-11. PubMed ID: 20095041
[TBL] [Abstract][Full Text] [Related]
16. Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer.
Ulazzi L; Sabbioni S; Miotto E; Veronese A; Angusti A; Gafà R; Manfredini S; Farinati F; Sasaki T; Lanza G; Negrini M
Mol Cancer; 2007 Feb; 6():17. PubMed ID: 17328794
[TBL] [Abstract][Full Text] [Related]
17. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma.
Tanaka K; Imoto I; Inoue J; Kozaki K; Tsuda H; Shimada Y; Aiko S; Yoshizumi Y; Iwai T; Kawano T; Inazawa J
Oncogene; 2007 Sep; 26(44):6456-68. PubMed ID: 17438526
[TBL] [Abstract][Full Text] [Related]
18. Isolation and enrichment of human genomic CpG islands by methylation-sensitive mirror orientation selection.
Huang Q; Baum L; Huang JF; You JP; Wang F; Wang J; Zheng J; Yan XC; Xia H; Zhao YH; Kuang H; Fu WL
Anal Biochem; 2007 Jun; 365(2):153-64. PubMed ID: 17481566
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
[TBL] [Abstract][Full Text] [Related]
20. Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1.
Metge BJ; Liu S; Riker AI; Fodstad O; Samant RS; Shevde LA
Oncology; 2010; 78(1):75-86. PubMed ID: 20215788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
